Chronic Pain Market, by Drug (Opioids, Non-steroidal anti-inflammatory drugs (NSAIDS), Anticonvulsants, Antidepressants, Others), by Indication (Neuropathic pain, Arthritis pain, Chronic back pain, Cancer pain, Migraine, Fibromyalgia and Others), by Appli

Chronic Pain Market, by Drug (Opioids, Non-steroidal anti-inflammatory drugs (NSAIDS), Anticonvulsants, Antidepressants, Others), by Indication (Neuropathic pain, Arthritis pain, Chronic back pain, Cancer pain, Migraine, Fibromyalgia and Others), by Application (Musculoskeletal, Neuropathy, Oncology, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Chronic pain is pain that is ongoing and usually lasts longer than six months. This type of pain can continue even after the injury or illness that caused it has healed or gone away. Pain signals remain active in the nervous system for weeks, months or years. Chronic pain is linked to conditions that include: Headache, Arthitis, Cancer, Nerve pain, Back pain, Fibromyalgia. Chronic pain also causes emotional effects, including: Depression, Anger, Anxiety. Drugs prescribed for the treatment of chronic pain are opioids, non-steroidal anti-inflammatory drugs (NSAIDS), anticonvulsants, antidepressants and others.

Market Dynamics

Key players are focused on product launches in order to expand their product portfolio. This is expected to propel the growth of the global chronic pain market during the forecast period. For instance, in February 2016, Endo Pharmaceuticals Inc., a subsidiary of Endo International plc, announced the availability of BELBUCA (buprenorphine) buccal film, the first and only buprenorphine formulation developed with a dissolving film that is absorbed through the inner lining of the cheek for chronic pain management. BELBUCA, distributed and promoted by Endo, is now available United States.

Increasing number of positive results of drugs is the major factor driving the market growth over the forecast period. For instance, in April 2017, VistaGen Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, announced the peer-reviewed publication of nonclinical studies of the effects of AV-101 (4-Cl-KYN), its CNS product candidate, in four well-established nonclinical models of pain.

Key features of the study:
This report provides an in-depth analysis of global chronic pain market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global chronic pain market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
Key companies covered as a part of this study include Eli Lilly and Company, GlaxoSmithKline plc., Pfizer Inc , Abbott Laboratories, Novartis AG, Johnson & Jonson, AstraZeneca plc, Bristol-Myers Squibb Company, Becton, Dickinson and Company, and Sanofi S.A..
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global chronic pain market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision making through various strategy matrices used in analyzing the Smart market
Detailed Segmentation:
Global Chronic Pain Market, By Drugs:
Opioids
Non- Steroidal anti- inflammatory drugs (NSAIDS)
Anticonvulsants
Anti drepressants
Others
Global Chronic Pain Market, By Indication:
Neuropathic Pain
Arthritis Pain
Chronic Back pain
Cancer pain
Migraine
Fibromyalgia
Others
Global Chronic Pain Market, By Application
Musculoskeletal
Neuropathy
Oncology
Others
Global Chronic Pain Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Chronic Pain Market, By Region:
North America
By Drugs:
Opioids
Non-steroidal anti-inflammatory drugs (NSAIDS)
Anticonvulsants
Antidepressants
Others
By Indication:
Neuropathic Pain
Arthritis Pain
Chronic Back Pain
Cancer Pain
Migraine
Fibromyalgia
Others
By Application:
Musculoskeletal
Neuropathy
Oncology
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.S.
Canada
Latin America
By Drugs:
Opioids
Non-steroidal anti-inflammatory drugs (NSAIDS)
Anticonvulsants
Antidepressants
Others
By Indication:
Neuropathic Pain
Arthritis Pain
Chronic Back Pain
Cancer Pain
Migraine
Fibromyalgia
Others
By Application:
Musculoskeletal
Neuropathy
Oncology
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Drugs:
Opioids
Non-steroidal anti-inflammatory drugs (NSAIDS)
Anticonvulsants
Antidepressants
Others
By Indication:
Neuropathic Pain
Arthritis Pain
Chronic Back Pain
Cancer Pain
Migraine
Fibromyalgia
Others
By Application:
Musculoskeletal
Neuropathy
Oncology
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
Asia Pacific
By Drugs:
Opioids
Non-steroidal anti-inflammatory drugs (NSAIDS)
Anticonvulsants
Antidepressants
Others
By Indication:
Neuropathic Pain
Arthritis Pain
Chronic Back Pain
Cancer Pain
Migraine
Fibromyalgia
Others
By Application:
Musculoskeletal
Neuropathy
Oncology
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
Middle East
By Drugs:
Opioids
Non-steroidal anti-inflammatory drugs (NSAIDS)
Anticonvulsants
Antidepressants
Others
By Indication:
Neuropathic Pain
Arthritis Pain
Chronic Back Pain
Cancer Pain
Migraine
Fibromyalgia
Others
By Application:
Musculoskeletal
Neuropathy
Oncology
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
GCC
Israel
Rest of Middle East
Africa
By Drugs:
Opioids
Non-steroidal anti-inflammatory drugs (NSAIDS)
Anticonvulsants
Antidepressants
Others
By Indication:
Neuropathic Pain
Arthritis Pain
Chronic Back Pain
Cancer Pain
Migraine
Fibromyalgia
Others
By Application:
Musculoskeletal
Neuropathy
Oncology
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Eli Lilly and Company *
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
GlaxoSmithKline plc.
Pfizer Inc.
Abbott Laboratories
Novartis AG
Johnson & Johnson
AstraZeneca plc.
Bristol-Myers Squibb Company
Becton, Dickinson and Company
Sanofi S.A.
“*” marked represents similar segmentation in other categories in the respective section.